SCH-442,416

SCH-442,416
Nazivi
	IUPAC naziv 2-(2-furil)-7-[3-(4-metoksifenil)propil]-7H-pirazolo[4,3-e][1,2,4]triazolo[1,5-c]pirimidin-5-amin
	Drugi nazivi SCH-442,416
Identifikacija
CAS broj	316173-57-6;
3D model (Jmol)	interaktivna slika;
ChemSpider	8843413 ;
PubChem C ID	10668061;
	SMILES n1n3c(nc4c(c3nc1c2occc2)cnn4CCCc5ccc(OC)cc5)N; ; ; ; ; ;
Svojstva
Hemijska formula	C20H19N7O2
Molarna masa	389,410
	Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa).
	verifikuj (šta je ?)
	Reference infokutije

SCH-442,416 je visoko selektivan antagonist adenozinskog A_2a receptora. On je u širokoj upotrebi u njegovoj ¹¹C radioobeleženoj formi za mapiranje distribucije A_2a receptora u mozgu.^[3] Uzimajući u obzir distribuciju A_2a receptora u mozgu, oni su istraživani za tretman raznih neuroloških poremećaja, i utvrđeno je da SCH-442,416 potencijalno može da nađe primenu u tretmanu depresije,^[4] Parkinsonove bolesti,^[5] i katalepsije.^[6]

Reference[уреди | уреди извор]

^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди
^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
^ Moresco RM, Todde S, Belloli S, Simonelli P, Panzacchi A, Rigamonti M, Galli-Kienle M, Fazio F. In vivo imaging of adenosine A2A receptors in rat and primate brain using [11C]SCH442416. European Journal of Nuclear Medicine and Molecular Imaging. 2005 Apr;32(4):405-13. PMID 15549298
^ El Yacoubi M, Costentin J, Vaugeois JM. Adenosine A2A receptors and depression. Neurology. 2003 Dec 9;61(11 Suppl 6):S82-7. PMID 14663017
^ Matsuya T, Takuma K, Sato K, Asai M, Murakami Y, Miyoshi S, Noda A, Nagai T, Mizoguchi H, Nishimura S, Yamada K. Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model. Journal of Pharmacological Sciences. 2007 Mar;103(3):329-32. PMID 17341841
^ Mihara T, Noda A, Arai H, Mihara K, Iwashita A, Murakami Y, Matsuya T, Miyoshi S, Nishimura S, Matsuoka N. Brain adenosine A2A receptor occupancy by a novel A1/A2A receptor antagonist, ASP5854, in rhesus monkeys: relationship to anticataleptic effect. Journal of Nuclear Medicine. 2008 Jul;49(7):1183-8. PMID 18552135

Spoljašnje veze[уреди | уреди извор]

Molecular Imaging and Contrast Agent Database: SCH-442,416

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди

[2] Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.

[3] Moresco RM, Todde S, Belloli S, Simonelli P, Panzacchi A, Rigamonti M, Galli-Kienle M, Fazio F. In vivo imaging of adenosine A2A receptors in rat and primate brain using [11C]SCH442416. European Journal of Nuclear Medicine and Molecular Imaging. 2005 Apr;32(4):405-13. PMID 15549298

[4] El Yacoubi M, Costentin J, Vaugeois JM. Adenosine A2A receptors and depression. Neurology. 2003 Dec 9;61(11 Suppl 6):S82-7. PMID 14663017

[5] Matsuya T, Takuma K, Sato K, Asai M, Murakami Y, Miyoshi S, Noda A, Nagai T, Mizoguchi H, Nishimura S, Yamada K. Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model. Journal of Pharmacological Sciences. 2007 Mar;103(3):329-32. PMID 17341841

[6] Mihara T, Noda A, Arai H, Mihara K, Iwashita A, Murakami Y, Matsuya T, Miyoshi S, Nishimura S, Matsuoka N. Brain adenosine A2A receptor occupancy by a novel A1/A2A receptor antagonist, ASP5854, in rhesus monkeys: relationship to anticataleptic effect. Journal of Nuclear Medicine. 2008 Jul;49(7):1183-8. PMID 18552135

[1]

[2]

[3]

[4]

[5]

[6]